403 related articles for article (PubMed ID: 22134068)
1. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
2. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
Sun JM; Han J; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
[TBL] [Abstract][Full Text] [Related]
3. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.
Kasai D; Ozasa H; Oguri T; Miyazaki M; Uemura T; Takakuwa O; Kunii E; Ohkubo H; Maeno K; Niimi A
Anticancer Res; 2013 May; 33(5):1935-40. PubMed ID: 23645741
[TBL] [Abstract][Full Text] [Related]
5. Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
Grønberg BH; Lund-Iversen M; Strøm EH; Brustugun OT; Scott H
J Thorac Oncol; 2013 Oct; 8(10):1255-64. PubMed ID: 24457236
[TBL] [Abstract][Full Text] [Related]
6. [Significance of molecular technology in diagnosis and therapy of non-small-cell lung cancer].
Chen XX; Zhou CC
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):570-2. PubMed ID: 23157756
[No Abstract] [Full Text] [Related]
7. Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.
Chamizo C; Zazo S; Dómine M; Cristóbal I; García-Foncillas J; Rojo F; Madoz-Gúrpide J
BMC Pulm Med; 2015 Oct; 15():132. PubMed ID: 26502926
[TBL] [Abstract][Full Text] [Related]
8. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.
Christoph DC; Asuncion BR; Hassan B; Tran C; Maltzman JD; O'Shannessy DJ; Wynes MW; Gauler TC; Wohlschlaeger J; Hoiczyk M; Schuler M; Eberhardt WE; Hirsch FR
J Thorac Oncol; 2013 Jan; 8(1):19-30. PubMed ID: 23242435
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
Ranson M; Reck M; Anthoney A; Hanauske AR; Dean E; Melezinek I; Klingelschmitt G; Kletzl H; Blatter J; Twelves C
Ann Oncol; 2010 Nov; 21(11):2233-2239. PubMed ID: 20444843
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Gadgeel SM; Ruckdeschel JC; Patel BB; Wozniak A; Konski A; Valdivieso M; Hackstock D; Chen W; Belzer K; Burger AM; Marquette L; Turrisi A
J Thorac Oncol; 2011 May; 6(5):927-33. PubMed ID: 21415776
[TBL] [Abstract][Full Text] [Related]
12. Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC).
Alvarez-Fernandez C; Perez-Arnillas Q; Ruiz-Echeverria L; Rodriguez-Rubi D; Sanchez-Lorenzo L; Li-Torres W; Izquierdo-Manuel M; Berros JP; Luque-Cabal M; Jimenez-Fonseca P; Villanueva-Palicio N; Esteban-Gonzalez E
Invest New Drugs; 2014 Apr; 32(2):377-81. PubMed ID: 23912258
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
Grabauskiene S; Bergeron EJ; Chen G; Thomas DG; Giordano TJ; Beer DG; Morgan MA; Reddy RM
J Surg Res; 2014 Mar; 187(1):6-13. PubMed ID: 24418519
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
Lee JO; Kim TM; Lee SH; Kim DW; Kim S; Jeon YK; Chung DH; Kim WH; Kim YT; Yang SC; Kim YW; Heo DS; Bang YJ
J Thorac Oncol; 2011 Sep; 6(9):1474-80. PubMed ID: 21642865
[TBL] [Abstract][Full Text] [Related]
16. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Shimizu T; Nakanishi Y; Nakagawa Y; Tsujino I; Takahashi N; Nemoto N; Hashimoto S
Anticancer Res; 2012 Oct; 32(10):4589-96. PubMed ID: 23060591
[TBL] [Abstract][Full Text] [Related]
17. P63 expression in lung carcinoma: a tissue microarray study of 408 cases.
Au NH; Gown AM; Cheang M; Huntsman D; Yorida E; Elliott WM; Flint J; English J; Gilks CB; Grimes HL
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):240-7. PubMed ID: 15551738
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase inhibitors for non-small cell lung cancer.
Galvani E; Peters GJ; Giovannetti E
Expert Opin Investig Drugs; 2011 Oct; 20(10):1343-56. PubMed ID: 21905922
[TBL] [Abstract][Full Text] [Related]
19. The place of pemetrexed in the management of non-small-cell lung cancer patients.
Tomasini P; Greillier L; Khobta N; Barlesi F
Expert Rev Anticancer Ther; 2013 Mar; 13(3):257-66. PubMed ID: 23477511
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
